HSK55718 dose level1: Patients administrated with HSK55718 at dose level 1
HSK55718 dose level2: Patients administrated with HSK55718 at dose level 2
HSK55718 dose level 3: Patients administrated with HSK55718 at dose level 3
Placebo control: Patients administrated with placebo
morphine: Patients administrated with morphine
Study summary
This is a multi-center, randomized, double-blind, double-dummy, placebo/active-controlled study. 200 subjects undergoing abdominal surgery under general anesthesia are planned to be enrolled and randomized into the HSK55718 group, morphine group, and placebo group.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years old, regardless of gender;
* 18 kg/m2≤BMI≤30 kg/m2;
* American Society of Anesthesiologists (ASA) gradeⅰ-ⅲ;
* Accept abdominal surgery under general anesthesia;
* Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;
* Fully understand and voluntarily participate this trial, and sign the informed consent form;
Exclusion Criteria:
* A history of cardiovascular, respiratory, neurological, or psychiatric diseases that meet the protocol-defined exclusion criteria.
* Clinically significant abnormalities in laboratory tests during the screening period.
* A history of severe drug allergy or known allergy to the investigational drug.
* Continuous use of opioid analgesics for more than 10 days for any reason within 3 months prior to randomization.
* Use of any medication that may affect analgesia, where the last dose was administered less than 5 half-lives of that drug before randomization.
* A history of drug abuse, substance abuse, and/or alcohol abuse within the past year.
* Pregnant or lactating women.
* Participation in another drug clinical trial within 3 months prior to the screening period.
* Presence of any sensory dysfunction.
* Presence of any painful physical condition.
* Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.
Primary outcome measure(s)
Sum of Pain Intensity Differences (SPID) — 24 hours
Trial sites (2)
Facility
City
Region
Status
The Third Xiangya Hospital of Central South University
Changsha
Hunan
Recruiting
Sichuan Provincial People's Hospital
Chengdu
Sichuan
Recruiting
More Haisco Pharmaceutical Group Co., Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.